About Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: Pharmaceuticals
- Exchange: NYSE
- Symbol: JNJ
- CUSIP: 47816010
- Previous Close: $123.51
- 50 Day Moving Average: $125.13
- 200 Day Moving Average: $118.21
- 52-Week Range: $2,713,346,000.00 - $109.32
- Trailing P/E Ratio: 20.76
- Foreward P/E Ratio: 16.10
- P/E Growth: 2.71
- Market Cap: $335.13B
- Outstanding Shares: 2,713,346,000
- Beta: 0.74
- Net Margins: 22.78%
- Return on Equity: 25.61%
- Return on Assets: 13.40%
- Debt-to-Equity Ratio: 0.32%
- Current Ratio: 2.73%
- Quick Ratio: 2.36%
Companies Related to Johnson & Johnson:
Earnings History for Johnson & Johnson (NYSE:JNJ)Earnings History by Quarter for Johnson & Johnson (NYSE:JNJ)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/18/2017|| || || || || || || || |
|4/18/2017||Q1 17||$1.77||$1.83||$18.02 billion||$17.77 billion||View||N/A|
|1/24/2017||Q416||$1.56||$1.58||$18.28 billion||$18.10 billion||View||N/A|
|10/18/2016||Q316||$1.65||$1.68||$17.71 billion||$17.80 billion||View||Listen|
|7/19/2016||Q216||$1.68||$1.74||$17.98 billion||$18.50 billion||View||Listen|
|4/19/2016||Q116||$1.65||$1.68||$17.50 billion||$17.50 billion||View||Listen|
|1/26/2016||Q415||$1.42||$1.44||$17.88 billion||$17.80 billion||View||Listen|
|10/13/2015||Q315||$1.45||$1.49||$17.47 billion||$17.10 billion||View||Listen|
|7/14/2015||Q215||$1.69||$1.71||$17.76 billion||$17.80 billion||View||Listen|
|4/14/2015||Q115||$1.54||$1.56||$17.31 billion||$17.37 billion||View||Listen|
|1/20/2015||Q414||$1.25||$1.27||$18.59 billion||$18.30 billion||View||Listen|
|10/14/2014||Q314||$1.42||$1.50||$18.41 billion||$18.50 billion||View||Listen|
|7/15/2014||Q214||$1.54||$1.66||$18.86 billion||$19.50 billion||View||N/A|
|4/15/2014||Q114||$1.48||$1.54||$18.00 billion||$18.10 billion||View||N/A|
|1/21/2014||Q413||$1.20||$1.24||$17.95 billion||$18.40 billion||View||N/A|
|10/15/2013||Q313||$1.32||$1.36||$17.46 billion||$17.60 billion||View||N/A|
|7/16/2013||Q2 2013||$1.39||$1.48||$17.71 billion||$17.90 billion||View||N/A|
|4/16/2013||Q1 2013||$1.41||$1.44||$17.46 billion||$17.50 billion||View||N/A|
|1/22/2013||Q4 2012||$1.17||$1.19||$17.67 billion||$17.60 billion||View||N/A|
Earnings Estimates for Johnson & Johnson (NYSE:JNJ)
2017 EPS Consensus Estimate: $6.99
2018 EPS Consensus Estimate: $7.79
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Johnson & Johnson (NYSE:JNJ)
|Most Recent Dividend:||3/14/2017|
|Dividend Growth:||6.70% (3 Year Average)|
|Payout Ratio:||54.42% (Trailing 12 Months of Earnings) |
45.07% (Based on This Year's Estimates)
41.72% (Based on Next Year's Estimates)
|Track Record:||54 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Johnson & Johnson (NYSE:JNJ)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Johnson & Johnson (NYSE:JNJ)
Insider Ownership Percentage: 0.11%Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Institutional Ownership Percentage: 65.30%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/15/2017||Paulus Stoffels||VP||Sell||22,000||$117.29||$2,580,380.00|| |
|10/21/2016||Charles Prince||Director||Buy||875||$114.11||$99,846.25|| |
|7/26/2016||Dominic J Caruso||VP||Sell||41,146||$125.01||$5,143,661.46|| |
|7/22/2016||Ronald A Kapusta||CAO||Sell||2,935||$125.01||$366,904.35|| |
|6/7/2016||Gary J Pruden||VP||Sell||9,735||$116.03||$1,129,552.05|| |
|6/7/2016||Ronald A Kapusta||CAO||Sell||3,000||$115.79||$347,370.00|| |
|5/10/2016||Ronald A Kapusta||CAO||Sell||3,957||$114.77||$454,144.89|| |
|2/17/2016||Paulus Stoffels||insider||Sell||125,000||$102.43||$12,803,750.00|| |
|2/3/2016||Peter Fasolo||VP||Sell||151,385||$104.12||$15,762,206.20|| |
|10/23/2015||Ronald A. Kapusta||CAO||Sell||6,239||$99.68||$621,903.52|| |
|6/2/2015||Charles Prince||Director||Buy||2,500||$99.22||$248,050.00|| |
|4/28/2015||Paulus Stoffels||Insider||Sell||187,250||$100.73||$18,861,692.50|| |
|9/10/2014||James Cullen||Director||Sell||2,446||$104.12||$254,677.52|| |
|5/5/2014||Stephen Cosgrove||Insider||Sell||22,000||$100.05||$2,201,100.00|| |
|3/14/2014||Peter Fasolo||VP||Sell||6,824||$93.15||$635,655.60|| |
|8/14/2013||Stephen Cosgrove||Insider||Sell||17,200||$91.39||$1,571,908.00|| |
|8/5/2013||Michael Ullmann||VP||Sell||16,140||$93.68||$1,511,995.20|| |
|7/25/2013||Paulus Stoffels||Insider||Sell||45,440||$92.40||$4,198,656.00|| |
|7/18/2013||Dominic J Caruso||CFO||Sell||30,000||$90.31||$2,709,300.00|| |
|11/12/2012||James Cullen||Director||Sell||13,900||$69.70||$968,830.00|| |
Headline Trends for Johnson & Johnson (NYSE:JNJ)
Latest Headlines for Johnson & Johnson (NYSE:JNJ)
Frequently Asked Questions for Johnson & Johnson (NYSE:JNJ)
What is Johnson & Johnson's stock symbol?
Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."
How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?
Johnson & Johnson declared a quarterly dividend on Tuesday, January 3rd. Stockholders of record on Tuesday, February 28th will be paid a dividend of $0.80 per share on Tuesday, March 14th. This represents a $3.20 annualized dividend and a dividend yield of 2.59%. The ex-dividend date is Friday, February 24th.
How were Johnson & Johnson's earnings last quarter?
Johnson & Johnson (NYSE:JNJ) issued its earnings results on Tuesday, April, 18th. The company reported $1.83 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.77 by $0.06. The firm earned $17.77 billion during the quarter, compared to analyst estimates of $18.02 billion. Johnson & Johnson had a return on equity of 25.61% and a net margin of 22.78%. The company's revenue was up 1.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.68 EPS.
When will Johnson & Johnson make its next earnings announcement?
Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, July, 18th 2017.
What guidance has Johnson & Johnson issued on next quarter's earnings?
Johnson & Johnson updated its FY17 earnings guidance on Tuesday, January, 24th. The company provided EPS guidance of $6.93-7.08 for the period, compared to the Thomson Reuters consensus estimate of $7.12. The company issued revenue guidance of $74.1-74.8 billion, compared to the consensus revenue estimate of $75.13 billion.
Where is Johnson & Johnson's stock going? Where will Johnson & Johnson's stock price be in 2017?
16 brokers have issued 1-year price objectives for Johnson & Johnson's stock. Their predictions range from $94.00 to $145.00. On average, they expect Johnson & Johnson's stock price to reach $125.41 in the next year.
What are analysts saying about Johnson & Johnson stock?
Here are some recent quotes from research analysts about Johnson & Johnson stock:
- 1. BTIG Research analysts commented, "JNJ reported 1Q17 financial results before market open that were generally below expectations. We had expected growth within the Pharmaceuticals segment to become challenging during 2017, but the weakness experienced within key cardiovascular and metabolic franchises, Xarelto and Invokana, amplified the declines of the Remicade franchise and growth moderation of other leading drug brands. During our discussion of the Actelion merger, we highlighted that commercial catalysts for JNJ’s key drug brands were generally reflected by analyst estimates, putting more pressure on the company to unveil new catalysts within the R&D pipeline at the Pharma Business Review on May 17th. We remain Neutral." (4/19/2017)
- 2. According to Zacks Investment Research, "J&J’s Pharma segment is performing well despite challenges like generic competition for a few products, potential biosimilar competition and lower HCV revenues. While Pfizer’s launch of biosimilar Remicade creates some uncertainty regarding the segment’s sales growth in 2017, we believe that the impact may be manageable. Contribution from new as well as core products, share buybacks and the restructuring initiative should help drive results. Estimates have remained mostly stable lately ahead of the Q4 earnings results. J&J has a positive record of earnings surprises in recent quarters. J&J's shares have surpassed that of large-cap pharma industry in 2016. However, headwinds persist in the form of generics and biosimilar competition and pricing pressure." (1/9/2017)
- 3. Jefferies Group LLC analysts commented, "With biosimilars and generics expected to drag the next few years, we expect JNJ will continue look to M&A to augment growth. Whilst this should ultimately drive better growth, we believe that investors will not reward the shares for this initially." (1/5/2017)
Who owns Johnson & Johnson stock?
Johnson & Johnson's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.41%), Bank of Montreal Can (0.25%), Russell Investments Group Ltd. (0.20%), PGGM Investments (0.12%), State of New Jersey Common Pension Fund D (0.12%) and Chevy Chase Trust Holdings Inc. (0.10%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta.
Who sold Johnson & Johnson stock? Who is selling Johnson & Johnson stock?
Johnson & Johnson's stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, Candriam Luxembourg S.C.A., Atalanta Sosnoff Capital LLC, Miller Howard Investments Inc. NY, Nationwide Fund Advisors, State of New Jersey Common Pension Fund D, PGGM Investments and Boston Advisors LLC. Company insiders that have sold Johnson & Johnson stock in the last year include Dominic J Caruso, Gary J Pruden, Paulus Stoffels and Ronald A Kapusta.
Who bought Johnson & Johnson stock? Who is buying Johnson & Johnson stock?
Johnson & Johnson's stock was bought by a variety of institutional investors in the last quarter, including Korea Investment CORP, Russell Investments Group Ltd., Acadian Asset Management LLC, Doyle Wealth Management, Fisher Asset Management LLC, Hexavest Inc., Janney Montgomery Scott LLC and Personal Capital Advisors Corp.
How do I buy Johnson & Johnson stock?
Shares of Johnson & Johnson can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Johnson & Johnson stock cost?
One share of Johnson & Johnson stock can currently be purchased for approximately $123.51.
Johnson & Johnson (JNJ) Chart for Thursday, April, 27, 2017